TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease SAN DIEGO, May 5,...
Read More Details
Finally We wish PressBee provided you with enough information of ( TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks )
Also on site :
- Anne Burrell's Husband Looks Somber in First Photo Since Food Network Star's Death
- Iran threatens US bases in Middle East, asserts nuclear facilities undamaged
- Trump’s Gulf Arab allies race to avoid all-out war in Iran